Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0061852 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0061852 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0061852 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.00567454 | 0.853467 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.00270026 | 0 | 0.5 |
Brugia malayi | flavodoxin family protein | 0.0061852 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0061852 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.00567454 | 0.853467 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0061852 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.00348493 | 0.22516 | 0.22516 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0061852 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0061852 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0061852 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0061852 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0061852 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0061852 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0061852 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0061852 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0061852 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0061852 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.00399559 | 0.371693 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0061852 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0061852 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0061852 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0061852 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0061852 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.00270026 | 0 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0061852 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0061852 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.00399559 | 0.371693 | 0.371693 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.65 ug ml-1 | Antimalarial activity against chloroquine ane quinine-sensitive ring stage of Plasmodium falciparum assessed as inhibition of parasite growth after 48 hrs | ChEMBL. | 25016227 |
Inhibition (functional) | = 22 % | Antituberculosis activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of colony formation at 250 ug/ml after 4 weeks of incubation | ChEMBL. | 25016227 |
MIC (functional) | = 500 ug ml-1 | Antimicrobial activity against Escherichia coli MTCC 443 assessed as absence of visible growth after 24 to 48 hrs by broth micro dilution method | ChEMBL. | 25016227 |
MIC (functional) | = 500 ug ml-1 | Antimicrobial activity against Candida albicans MTCC 227 assessed as absence of visible growth after 24 to 48 hrs by broth micro dilution method | ChEMBL. | 25016227 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 25016227 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.